June 29 (Reuters) - Genmab A/S:
* REG-GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER
* GENMAB AND SEATTLE GENETICS PLAN TO DISCUSS RESULTS WITH U.S. FOOD AND DRUG ADMINISTRATION
* TISOTUMAB VEDOTIN IS BEING DEVELOPED IN COLLABORATION WITH SEATTLE GENETICS Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.